BioPorto A/S | Cash Flow

Fiscal year is January-December. All values DKK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
19,802.00
15,256.00
12,759.00
25,047.00
36,494.00
41,781
Depreciation, Depletion & Amortization
107.00
270.00
300.00
390.00
504.00
543
Other Funds
387.00
160.00
1,897.00
4,158.00
4,266.00
3,860
Funds from Operations
20,082.00
14,826.00
10,562.00
20,499.00
31,724.00
37,378
Changes in Working Capital
3,442.00
1,312.00
6,012.00
839.00
2,325.00
631
Net Operating Cash Flow
16,640.00
16,138.00
16,574.00
19,660.00
29,399.00
38,009
Capital Expenditures
28.00
807.00
514.00
357.00
38.00
Sale of Fixed Assets & Businesses
-
-
18.00
-
-
Purchase/Sale of Investments
5.00
392.00
21.00
44.00
-
Net Investing Cash Flow
33.00
1,199.00
517.00
401.00
59.00
Issuance/Reduction of Debt, Net
5,510.00
18.00
20.00
22.00
24.00
Net Financing Cash Flow
51,126.00
18.00
26,511.00
20,836.00
40,897.00
Net Change in Cash
34,453.00
17,355.00
9,420.00
775.00
11,439.00
Free Cash Flow
16,668.00
16,680.00
16,624.00
19,817.00
29,437.00
Change in Capital Stock
56,636.00
-
26,531.00
20,858.00
40,921.00
Other Uses
-
-
-
-
21.00

About BioPorto A/S

View Profile
Address
Tuborg Havnevej 15
Hellerup CR 2900
Denmark
Employees -
Website http://www.bioporto.com
Updated 07/08/2019
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. Its products specialize in coagulation, immunodeficiencies, diabetes, peptide hormones, and kidney diseases. Its portfolio consists of NGAL Test, NGAL ELISA kits, MBL ELISA kits, and AntibodyShop.